Acacetin Ameliorates Hyperuricemia by Regulating Uric Acid Transporter and NF-κB/NLRP3 Signaling Pathway
10.13422/j.cnki.syfjx.20241711
- VernacularTitle:刺槐素通过调控尿酸转运蛋白和NF-κB/NLRP3信号通路改善高尿酸血症
- Author:
Xuanxia WU
1
;
Juan BU
1
;
YELEDAN·MAHAN
1
;
Shengnan ZHANG
2
;
Xiaoling ZHANG
1
;
Ling ZHOU
1
Author Information
1. People's Hospital of Xinjiang Uygur Autonomous Region， Urumqi 830001， China
2. College of Life Sciences， Xinjiang University， Urumqi 830049， China
- Publication Type:Journal Article
- Keywords:
hyperuricemia;
acacetin;
uric acid transporter;
nuclear factor （NF）-κB/nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 （NLRP3） signaling pathway;
inflammation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(1):191-198
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the uric acid-lowering effects and mechanisms of acacetin on hyperuricemia （HUA） in mice. MethodsOteracil potassium and adenine were used to establish the mouse model of HUA. Male Kunming mice （n=48） were randomized into six groups： control， model， low-dose （12.5 mg·kg-1） acacetin， medium-dose （25 mg·kg-1） acacetin， high-dose （50 mg·kg-1） acacetin， and allopurinol （10 mg·kg-1）. Each group received continuous gavage administration for 21 days. An automatic biochemical analyzer was used to measure the levels of uric acid （UA）， creatinine （Cr）， urea nitrogen （BUN）， alanine aminotransferase （ALT） and aspartate aminotransferase （AST）. Additionally， the activity of xanthine oxidase （XOD） in the liver and the levels of tumor necrosis factor （TNF）-α， interleukin （IL）-1β， and IL-18 in the serum were measured by enzyme-linked immunosorbent assay （ELISA）. Pathological changes in the renal tissue were observed by hematoxylin-eosin （HE） staining. Western blot was employed to determine the levels of glucose transporter 9 （GLUT9）， urate transporter 1 （URAT1）， phospho-NF-κB p65 （p-NF-κB p65）， and nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 （NLRP3） in the renal tissue. ResultsCompared with the control group， the model group showed elevated levels of UA， Cr， BUN， ALT， and AST， increased activity of XOD in the liver（P<0.01）， raised levels of TNF-α， IL-1β and IL-18 in the serum（P<0.01）， and significantly up-regulated expression of GLUT9， URAT1， p-NF-κB p65， and NLRP3 in the renal tissue（P<0.01）. Compared with the model group， acacetin reduced the UA level in a dose-dependent manner， significantly improved liver and kidney functions， decreased the XOD activity in the liver， ameliorated the pathological changes in the renal tissue， down-regulated the expression of GLUT9， URAT1， p-NF-κB p65 and NLRP3 in the renal tissue（P<0.01）， and lowered the levels of TNF-α， IL-1β， and IL-18 in the serum（P<0.01）. ConclusionAcacetin can ameliorate HUA by decreasing uric acid production， increasing uric acid excretion， and inhibiting the NF-κB/NLRP3 signaling pathway. Therefore， acacetin may be a potential drug for the treatment of HUA.
